<DOC>
	<DOCNO>NCT01086332</DOCNO>
	<brief_summary>This study design evaluate nelfinavir work radiation sensitizer combination gemcitabine ( chemotherapy ) . We also look establish maximum dose gemcitabine tolerate nelfinavir radiation therapy , dose gemcitabine increase base previous trial participant tolerate dose gemcitabine .</brief_summary>
	<brief_title>Evaluation Nelfinavir Chemoradiation Pancreatic Cancer</brief_title>
	<detailed_description>This trial utilizes gemcitabine ( chemotherapy agent commonly use pancreatic cancer ) nelfinavir ( anti-retroviral agent FDA-approved use HIV+ patient ) addition radiation therapy treatment borderline resectable pancreatic cancer . The trial seek determine maximum tolerate dose gemcitabine administer concurrently radiation therapy 1250 mg nelfinavir twice daily . The gemcitabine radiation standard ; dose gemcitabine vary nationally internationally 'best dose ' . Administered weekly , dose range 400 mg/m2 1000 mg/m2 . Thus , propose clinical trial escalates gemcitabine . The gemcitabine administer weekly radiation therapy total 6 cycle . After completion radiation therapy , subject evaluate surgeon resectability . This end active portion clinical trial ; subject follow long-term progression free survival overall survival . Primary endpoint trial identify maximum tolerate dose gemcitabine administer concurrently nelfinavir radiation therapy ( phase I portion study ) rate resectability ( typically , utilize gemcitabine plus radiation therapy convert 30 % patient borderline resectable resectable ) phase II portion study . Interim analyse stop rule place effect size observe therapeutic group compare publish report response standard chemoradiation borderline resectable case .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<criteria>Closed accrual .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>radiotherapy</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>nelfinavir</keyword>
	<keyword>neoplasm</keyword>
</DOC>